SCHEMBL4090410

SCHEMBL4090410

CCCCN(C)c1nc(-c2ccccc2Cl)nc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
CYP1A2 P05177 4/20 0.61
CYP2D6 P10635 4/20 0.61
CYP2C19 P33261 3/20 0.61
LMNA P02545 2/20 0.61
CYP3A4 P08684 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.53
GBA1 P04062 3/20 0.51
MAPK1 P28482 3/20 0.50
TSPO P30536 3/20 0.50
CYP2C9 P11712 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
LATS1 O95835 1/20 0.49
LATS2 Q9NRM7 1/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
TSHR P16473 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857324 0.83 MAPT (0.66) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL4090908 0.82 CYP1A2 (0.71) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL1084232 0.81 MAPT (0.52) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL4095327 0.81 CYP1A2 (0.55) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL1083911 0.81 CYP2D6 (0.70) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL1083853 0.80 ACP1 (0.67) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL4092298 0.78 CYP1A2 (0.59) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL13300275 0.77 CYP1A2 (0.47) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL4095595 0.76 CYP1A2 (0.57) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL13984420 0.74 MAPT (0.56) MAPTCYP1A2CYP2D6CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MAPT 4125/4885CYP1A2 2477/4885CYP2D6 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.